Peter Hoehn, Accomplished Pharmaceutical Executive, Joins Cohen Veterans Bioscience (CVB) in Newly Created Executive Leadership Role

Peter Hoehn
Peter Hoehn joins Cohen Veterans Bioscience (CVB) as Executive Vice President, Strategic Marketing, Development, and Impact. In this newly created role, Hoehn will lead the External Affairs, Communications, and Development functions for New York-based non-profit CVB which is dedicated to advancing brain health.

Peter Hoehn joins Cohen Veterans Bioscience (CVB) as Executive Vice President, Strategic Marketing, Development, and Impact. In this newly created role, Hoehn will lead the External Affairs, Communications, and Development functions for New York-based non-profit CVB which is dedicated to advancing brain health. Hoehn will report to CVB Founder, CEO and President Dr. Magali Haas, MD, PhD.

Peter Hoehn is a proven healthcare business leader with 25+ years’ experience in a variety of commercial and strategy roles, predominantly at Johnson & Johnson. Hoehn was most recently Head, Commercial Strategy for J&J Science for Minds, a new organization focused on innovative development models and digital solutions to address serious mental illness and dementia. In this position he developed the strategy, portfolio recommendations, investment approach, external collaborations, and business models for new mental health and brain health digital business ventures.

“We are thrilled to have Peter join CVB in this new and important leadership role. I have had the privilege of partnering with Peter to advance brain therapeutics during our joint tenure at Johnson & Johnson and, more recently, in his capacity on the Steering Committee of the CVB-led Brain Health Nexus initiative. I am certain he will add impactful healthcare business expertise to our organization at a time of intense growth and development,” said Dr. Haas.

Throughout his career Peter has demonstrated the ability to develop insight-driven strategies in complex markets and mobilize internal and external partners to achieve results. He brings broad-based commercial, strategy and leadership experiences across Pharmaceuticals, Diagnostics, Digital Health, and Precision Medicine, including brand positioning and messaging, reimbursement and market access, global launches, organizational capability building, business model innovation, new opportunity evaluation, business development, and policy.

Peter started his career as a corporate lawyer and entered the pharmaceutical industry as an attorney for Bristol Myers Squibb. After a short time as a lawyer Peter moved into various strategy, marketing, and sales management roles at BMS before joining Johnson & Johnson in 2003.

Peter received a BA in Government and Economics from the College of William and Mary, and a JD from New York University.

View this press release on PR Newswire

Share this article:

More from CVB

https://www.cohenveteransbioscience.org/wp-content/uploads/2024/01/cv.webp

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

https://www.cohenveteransbioscience.org/wp-content/uploads/2022/11/bigstock-Dna-With-Unique-Connection-155670029.jpg

New meta-analysis builds upon PTSD genetics research, providing a foundation for the development of precision therapies

https://www.cohenveteransbioscience.org/wp-content/uploads/2023/03/what-is-post-traumatic-stress-disorder-ptsd-scaled.jpeg

Driving Progress: TBI Action Alliance Launches Multi-Pronged Initiative to Speed Development of Diagnostic and Therapeutic Solutions for Traumatic Brain Injury

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

For Media Inquiries

Please feel free to email us at media@cohenbio.org